Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion

Core Viewpoint - Sanofi has announced a share buyback program of up to €1 billion, set to take place between February 3, 2026, and December 31, 2026 [1] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare and societal challenges [2] Share Buyback Program Details - The share buyback program is authorized for a total consideration of up to €1 billion, with a mandate signed with an investment service provider on February 2, 2026 [1][6]